Quest Diagnostics offers defensive duopoly economics and accelerating outsourcing and advanced-diagnostics growth, but policy risks limit near-term upside at 21.42x normalized earnings.
Overview
Quest Diagnostics (DGX) is the leading U.S. clinical reference laboratory, processing approximately 244 million patient requisitions annually and serving roughly one in three American adults and half of U.S. physicians and hospitals. Diagnostic Information Services contribute approximately 98% of revenue, supported by a diversified payer mix: commercial insurers 37%, client payers 32%, government programs 16%, and direct patient payments 13%. **Q2 2026 demonstrated strong execution:** revenue increased 10.2% year over year to $3,043 million, organic growth was 10.0%, requisition volume rose 13.1%, adjusted EPS increased 19.1% to $3.12, and operating cash flow reached $597 million. Management raised 2026 revenue guidance to $11.95–$12.05 billion and adjusted EPS guidance to $11.05–$11.25. The investment case combines a duopoly-scale moat, hospital outsourcing, advanced oncology and neurology testing, and disciplined capital returns. At $227.86, DGX trades at 21.42x normalized P/E versus Labcorp’s 17.61x, reflecting higher-quality pure-play cash flows. Near-term catalysts include Corewell and Fresenius volume ramping, Haystack commercialization, margin improvement after the fourth quarter 2026, and analyst target increases to $245–$250. The principal counterweights are OBBBA coverage losses, PAMA reimbursement pressure, Project Nova execution risk, and a 50–60 basis-point long-term revenue headwind by 2028.